XML 74 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborations and Other Arrangements (Narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Jul. 31, 2023
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     $ 34,124.1 $ 28,541.4 $ 28,318.4
Proceeds from sale of product rights     1,604.3 95.8 216.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Olanzapine Portfolio          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from sale of product rights $ 1,050.0        
Consideration received $ 305.0        
Milestone payment received     25.0    
Revenue recognized     1,450.0    
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Olanzapine Portfolio | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestone payment received     50.0    
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baqsimi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from sale of product rights   $ 500.0      
Consideration received   $ 125.0      
Milestone payment received     450.0    
Revenue recognized     579.0    
Olumiant          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     $ 922.6 830.5 1,115.1
Olumiant | Royalty Payments Received          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations percent (up to)     20.00%    
Olumiant | Milestone Payments, Development and Regulatory          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     $ 100.0    
Ebglyss | Milestone Payments, Development and Regulatory | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     115.0    
Ebglyss | Milestone Payments, Sales-based          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     1,250.0    
Ebglyss | Milestone Payments, Sales-based | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     1,030.0    
Orforglipron | Milestone Payments, Development and Regulatory | Chugai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     140.0    
Orforglipron | Milestone Payments, Sales-based | Chugai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements     $ 250.0    
COVID-19 Antibodies          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue       $ 2,020.0 $ 2,240.0